Morin reverses P-glycoprotein-mediated multidrug-resistance in KBChR-8-5 cancer cell lines

Yan Zhao1, Sanhui Xu2, Weiting Hao1

  • 1Department of Stomatology, Xingtai People's Hospital, Xingtai, Hebei Province, China.

PubMed

Insights

Morin, a dietary flavonoid, effectively reverses paclitaxel resistance in multidrug-resistant (MDR) cancer cells by inhibiting P-glycoprotein (P-gp) and restoring chemotherapy efficacy. This study highlights morin

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cancer Biology

Background:

  • Multidrug resistance (MDR) significantly hinders cancer chemotherapy efficacy.
  • Adenosine triphosphate-binding cassette (ABC) transporters, particularly P-glycoprotein (P-gp), are key mediators of MDR.
  • Dietary flavonoids like morin are being investigated for their potential to overcome drug resistance.

Purpose of the Study:

  • To investigate morin's ability to overcome colchicine resistance in KBChR-8-5 MDR cells.
  • To evaluate morin's inhibitory effects on P-gp function and expression.
  • To assess the combined effect of morin and paclitaxel on apoptosis and cell cycle progression.

Main Methods:

  • Calcein-AM drug efflux assay to measure P-gp inhibitory activity.
  • Western blot analysis for P-gp mRNA and protein expression.
  • Flow cytometry and acridine orange/ethidium bromide staining for apoptosis and cell cycle analysis.
  • Polymerase chain reaction (PCR) array analysis for gene expression profiling.

Main Results:

  • Morin demonstrated strong binding to human P-gp, reducing its efflux function in a dose-dependent manner.
  • Combination treatment with morin and paclitaxel enhanced apoptosis induction and G2/M phase cell cycle arrest.
  • Morin treatment downregulated ABCB1 gene and P-gp membrane expression.
  • PCR array analysis showed morin and paclitaxel upregulated pro-apoptotic and cell cycle arrest genes while downregulating anti-apoptotic genes.

Conclusions:

  • Morin effectively reverses paclitaxel resistance in MDR cancer cells.
  • Morin resensitizes drug-resistant cancer cells to paclitaxel by targeting P-gp.
  • Morin holds potential as an adjuvant therapy to improve chemotherapy outcomes in resistant cancers.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
335